McCann, Eilish
Chehade, Mirna
Spergel, Jonathan M.
Yaworsky, Andrew
Symonds, Tara
Stokes, Jonathan
Tilton, Sarette T.
Sun, Xian
Kamat, Siddhesh
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi Global
Article History
Received: 3 July 2023
Accepted: 2 November 2023
First Online: 27 November 2023
Declarations
:
: The analysis presented here used data from the pivotal, randomized, placebo-controlled, multinational phase 3 R668-EE-1774 trial (NCT03633617). The local institutional review board or ethics committee at each trial center oversaw the conduct and documentation of the trial. Written informed consent or assent (or both) was obtained from all the patients or their parent or legal guardian before enrollment.
: Not applicable.
: STT is an employee of Sanofi Global and may hold stocks and/or shares in the company. EM, SK, and XS are employees of Regeneron Pharmaceuticals and may hold shares and/or stock options in the company. AY is an employee of Adelphi Values who developed the EoE-IQ as part of research funded by Regeneron Pharmaceuticals, and JS was an employee of Adelphi Values at the time the research was conducted. TS is an employee of Clinical Outcomes Solutions, who conducted research used to further develop the EoE-IQ, as part of research funded by Regeneron Pharmaceuticals. MC has received consultant fees from Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb, Phathom, Nexstone Immunology, and Recludix Pharma and has received research funding from Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Bristol Myers Squibb, and Danone . JMS has grant support and consultant fees from Regeneron and Sanofi.